Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

L.A. McKeown

October 09, 2024

News Daily News

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

Michael O'Riordan

June 25, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

News Daily News

Kidney Events High in Older Patients After HF Hospitalization

L.A. McKeown

May 30, 2024

News Conference News

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Michael O'Riordan

March 22, 2024

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

Todd Neale

August 08, 2023

News Daily News

US Athlete’s Death Highlights Risk of Hypertensive Disorders of Pregnancy

Michael O'Riordan

June 19, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Shelley Wood

May 16, 2021

Advertisement

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

GLP-1 Drugs May Have Role in Secondary Prevention of AF

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Top General Cardiology and Prevention News of 2024

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

Kidney Events High in Older Patients After HF Hospitalization

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

US Athlete’s Death Highlights Risk of Hypertensive Disorders of Pregnancy

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

January 2023 News Roundup

November 2022 News Roundup

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

July 2022 News Roundup

April 2022 News Roundup

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content